Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study

Abstract Background Treatment of postmenopausal, hormone receptor-positive metastatic breast cancer (MBC) patients varies despite clear therapy guidelines, favoring endocrine treatment (ET). Aim of this study was to analyze persistence of palliative aromatase inhibitor (AI) monotherapy in MBC patien...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Markus Wallwiener, Naiba Nabieva, Manuel Feisst, Tanja Fehm, Johann de Waal, Mahdi Rezai, Bernd Baier, Gerold Baake, Hans-Christian Kolberg, Martin Guggenberger, Mathias Warm, Nadia Harbeck, Rachel Wuerstlein, Jörg-Uwe Deuker, Peter Dall, Barbara Richter, Grischa Wachsmann, Cosima Brucker, Jan Willem Siebers, Milos Popovic, Thomas Kuhn, Christopher Wolf, Hans-Walter Vollert, Georg-Peter Breitbach, Wolfgang Janni, Robert Landthaler, Andreas Kohls, Daniela Rezek, Thomas Noesselt, Gunnar Fischer, Stephan Henschen, Thomas Praetz, Volker Heyl, Thorsten Kühn, Thomas Krauss, Christoph Thomssen, Andre Hohn, Hans Tesch, Christoph Mundhenke, Alexander Hein, Claudia Rauh, Christian M. Bayer, Katja Schmidt, Erik Belleville, Sara Y. Brucker, Peyman Hadji, Matthias W. Beckmann, Diethelm Wallwiener, Sherko Kümmel, Andreas Hartkopf, Peter A. Fasching
Formato: Artigo
Idioma:Inglês
Publicado: BMC 2019-06-01
Series:BMC Cancer
Assuntos:
Advanced/metastatic breast cancer
Palliative/metastatic treatment
Compliance
Persistence
Endocrine treatment/therapy
Aromatase inhibitor
Acceso en liña:http://link.springer.com/article/10.1186/s12885-019-5806-y
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares